From USFDA
Glenmark Pharmaceuticals announced that Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Adminstration for Rolaxifene Hydrochloride Tablets USP, 60 mg, the therapeutic equivalent to the reference listed drug product, Evista Tablets, 60 mg of Eli Lilly and Company.According to IMS Health sales data for 12 month period ending January 2016, the Evista Market achieved annual sales of approximately $ 336.5 million.
Powered by Capital Market - Live News
